Pharmacyclics Submits New Drug Application For Xcytrin For The Treatment Of Lung Cancer Brain Metastases

... Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has submitted a New Drug Application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection with the U.S. Food and Drug Administration (FDA). The company is seeking approval to market Xcytrin for the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (i.e. [click link for full article] ...